Scientific Publications and Presentations
Ribon Scientific Publications and Presentations
Gozgit et al., PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity, Cancer Cell (2021), https://doi.org/10.1016/j.
Gozgit J, Vasbinder MM, Abo R et al. RBN-2397: A potent and selective small molecule inhibitor of PARP7 that induces tumor-derived antitumor immunity dependent on CD8 T cells. April 2021 AACR 2021 Virtual Annual Meeting. Presentation | Video
Shambarkhar PB, Blackwell DJ, Vasbinder MM et al. Small molecule inhibitor of CD38 modulates its intra- and extracellular functions leading to antitumor activity. April 2021 AACR 2021 Virtual Annual Meeting. Poster | Audio
Wigle T, Ren Y, Molina JR et al. Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule. ChemBioChem (2021). https://doi.org/10.1002/cbic.
Schenkel et al., A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants. Cell Chemical Biology (2021), https://doi.org/10.1016/j.chembiol.2021.02.010.
Wigle TJ, Blackwell DJ, Schenkel LB, Ren Y, Church DW, Desai, HJ, Swinger KK, Santospago AG, Majer CR, Lu AZ, Niepel M, Perl NR, Vasbinder MM, Keilhack H, Kuntz KW. In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement. Cell Chemical Biology (2020); 27:877-887. doi: 10.1016/j.chembiol.2020.06.009.
Gozgit, JM. PARP7 negatively regulates the Type I interferon response in cancer cells and its inhibition leads to tumor regression. June 2020 American Association of Cancer Research (AACR) Virtual Annual Meeting II. Presentation | Video
Wigle TJ, Blackwell DJ, Schenkel LB, Swinger KK, Vasbinder MM, Ren Y, Church WD, Majer CR, Desai HJ, Perl NR, Santospago AG, Lu AZ, Niepel M, Keilhack H, Kuntz KW. A bespoke screening platform to study mono(ADP-ribosylation). 2020 American Association of Cancer Research (AACR) Virtual Annual Meeting II. Poster | Audio
Abo RP, Niepel M, Keilhack, H. A multi-omic characterization of PARP enzymes in cancer to identify novel monoPARP drug targets. June 2020 American Association of Cancer Research (AACR) Virtual Annual Meeting II. Poster | Audio
Vasbinder MM, Gozgit JM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, Lu AZ, Swinger KK, Wigle TJ, Blackwell DJ, Majer CR, Ren Y, Niepel M, Varsamis ZA, Nayak SP, Bamberg E, Mo JR, Church WD, Song J, Utley L, Rao PE, Mitchison TJ, Kuntz KW, Richon VM, Keilhack H. RBN-2397 – A First-in-Class PARP7 Inhibitor Targeting a Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways. April 2020 American Association of Cancer Research (AACR) Virtual Annual Meeting I. Presentation | Video
Schenkel L, Molina J, Swinger KK, Abo RP, Blackwell DJ, Cheung A, Church WD, Kuplast-Barr KG, Lu AZ, Minissale E, Niepel M, Vasbinder MM, Wigle TJ, Richon VM, Keilhack H, Kuntz KW. RBN012759 – A Potent and Selective PARP14 Inhibitor Decreases Pro-tumor Macrophage Function and Elicits Inflammatory Responses in Tumor Explants. April 2020 American Association of Cancer Research (AACR) Virtual Annual Meeting I. Presentation | Video
Wigle TJ, Church WD, Majer CR, Swinger KK, Aybar D, Schenkel LB, Vasbinder MM, Brendes A, Beck C, Prahm M, Wegener D, Chang P, Kuntz KW. Forced Self-Modification Assays as a Strategy to Screen MonoPARP Enzymes. SLAS Discovery (2019); doi: 10.1177/2472555219883623.
Church WD, Majer CR, Swinger KK, Aybar D, Santospago AG, Perl NR, Schenkel LB, Vasbinder MM, Kuntz KW, Wigle TJ. Development of Novel Biochemical Assays for the Screening of MonoPARP Enzymes. Society for Laboratory Automation and Screening (SLAS) January 2020 International Conference and Exhibition.
Lu AZ, Abo R, Ren Y, Gui B, Mo J, Blackwell D, Wigle TJ, Keilhack H, Niepel M. Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation. Biochem Phamacol (2019); 167:97-106. doi: 10.1016/j.bcp.2019.05.007.
Lu AZ, Najjar R, Niepel M, Stokes M. Novel antibody reagents for the characterization of protein ADP-ribosylation. April 2018 Cold Springs Harbor Laboratory Meeting on the PARP Family and ADP-Ribosylation.
Swinger K, Wigle TJ, Wei P, Zhang S, Tong S, Chang P, Kuntz KW. Co-crystal structure of PARP16 bound to its physiological cofactor NAD+. April 2018 Cold Springs Harbor Laboratory Meeting on the PARP Family and ADP-Ribosylation.
Selected Scientific References
Cellular Stress and Disease
Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. (2009); 136(5): 823-37. doi: 10.1016/j.cell.2009.02.024.
Paludan SR, Reinert, Ls, Hornung V. DNA-stimulated cell death: implications for host defence, inflammatory diseases and cancer. Nat Rev Immunol. (2019); 19(3): 141-153. doi: 10.1038/s41577-018-0117-0.
Costa-Mattioli M, Walter P. The integrated stress response: From mechanism to disease. Science (2020); 368 (6489): eaat5314. doi: 10.1126/science.aat5314
Luscher B, et al. ADP-ribosyltransferases, an update on function and nomenclature. FEBS. (2021). https://doi.org/10.1111/FEBS.
Bock FJ, Chang P. New Directions in PARP Biology. FEBS J. (2016); doi: 10.1111/febs.13737.
Kim D-S, Challa S, Jones A, Kraus WL. PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis. Genes Dev. (2020 Mar); doi: 10.1101/gad.334433.119.
Vyas S, Matic I, Uchima L, Rood J, Zaha R, Hay RT, Ahel I, Chang P. Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat Commun. (2014); 5:4426. doi: 10.1038/ncomms5426.
Vyas S, Chang P. New PARP targets for cancer therapy. Nat Rev Cancer (2014); 14:502-9. doi: 10.1038/nrc3748.
Cohen MS, Chang P. Insights into the biogenesis, function, and regulation of ADP-ribosylation. Nat Chem Biol. (2018); doi: 10.1038/nchembio.2568.